1-2 of 2
Jeffrey A. Barnes
Close
Sort by
Journal Articles

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma

Clinical Trials & Observations
Jeremy S. Abramson, Elizabeth Bengston, Robert Redd, Jeffrey A. Barnes, Tak Takvorian, Lubomir Sokol, Frederick Lansigan, Philippe Armand, Bijal Shah, Eric Jacobsen, Rosalba Martignetti, Elyce Turba, Sara Metzler, Victoria Patterson, Ann S. LaCasce, Celeste M. Bello
Journal: Blood Advances
Blood Adv (2023) 7 (7): 1130–1136.
https://doi.org/10.1182/bloodadvances.2022008420
Published: 2023
Journal Articles

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

Clinical Trials & Observations
J. Erika Haydu, Jenny S. Maron, Robert A. Redd, Kathleen M. E. Gallagher, Stephanie Fischinger, Jeffrey A. Barnes, Ephraim P. Hochberg, P. Connor Johnson, R. W. Takvorian, Katelin Katsis, Daneal Portman, Jade Ruiters, Sidney Sechio, Mary Devlin, Connor Regan, Kimberly G. Blumenthal, Aleena Banerji, Allen D. Judd, Krista J. Scorsune, Brianne M. McGree, Maryanne M. Sherburne, Julia M. Lynch, James I. Weitzman, Matthew Lei, Camille N. Kotton, Anand S. Dighe, Marcela V. Maus, Galit Alter, Jeremy S. Abramson, Jacob D. Soumerai
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1671–1683.
https://doi.org/10.1182/bloodadvances.2021006627
Published: 2022
Includes: Supplemental data